Author:
D'Amico Ferdinando,Solitano Virginia,Aletaha Daniel,Hart Ailsa,Magro Fernando,Selmi Carlo,Ng Siew C.,Al Awadhi Sameer,Choy Ernest,Schulze-Koops Hendrik,Bossuyt Peter,Olivera Pablo A.,Kotze Paulo Gustavo,Ghosh Subrata,Peyrin-Biroulet Laurent,Danese Silvio
Subject
Immunology,Immunology and Allergy
Reference50 articles.
1. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD);Danese;J Crohns Colitis,2013
2. Information guide for healthcare professionals;European Medicines Agency. Biosimilars in the EU;Biosimilar Drug Prod Dev,2017
3. Biosimilar Development, Review, and Approval | FDA 2021 [https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval accessed 25 January 2021].
4. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice;Solitano;Expert. Rev. Clin. Immunol.,2020
5. Biosimilars versus ‘biobetters’—a regulator’s perspective;Anour;GaBI J,2014
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献